NanoCMP™ Protein Vaccine Delivery Platform
Protein/peptide vaccines account for almost half of the field of cancer vaccine research. In addition to the selection of specific, well-targeted targets, accurate and efficient delivery of antigenic components to target tissue or target cells is also an important part of developing successful tumor vaccines. Creative Biolabs has a wealth of technology and experience in the research of tumor vaccines. In order to complement it to further improve the efficacy of vaccines, we have also spent a lot of effort into developing vaccine delivery technologies.
Background
Nanomaterials have specific physicochemical properties as well as structures of 100 nm or smaller in size compared to bulk materials of the same composition. The use of nanoparticle-delivered drugs can enhance the absorption of poorly water-soluble drugs, prolong the efficacy of drugs, improve the bioavailability of drugs, and improve patient compliance. By modulating the physicochemical parameters of the nanoparticles, cellular uptake, protein binding, clearance, metabolism, and targeted transport of the drug can be regulated.
Pullulan is a natural linear polysaccharide that is used as a macromolecular drug carrier because it is highly water-soluble, edible, non-toxic, non-mutating, non-immunogenic, and rich in hydroxyl group (convenient for chemical modification). Moreover, many studies have shown that some amphoteric pullulan derivatives have the ability to self-assemble into nanoparticles and thus can be used for drug delivery. CMP (cholesteryl-modified pullulan) is such a derivative.
NanoCMP™ - An Excellent Technology for Protein Vaccines
NanoCMP™ is based on the above principles. Pullulan is chemically modified to add cholesteryl to increase its hydrophobicity, and the resulting cholesteryl-modified pullulan-CMP can self-assemble into spherical nanoparticles under physiological conditions. The CMP particles can accommodate a variety of substances, especially has a unique advantage in embedding protein. This property allows it to stabilize and fold proteins. And it is gratifying to note that protein antigens delivered by NanoCMP™ are capable of simultaneously strongly activating antigen-specific killer T cells and helper T cells. This ability is different from protein vaccines that only produce helper T cells after immunization with a protein alone, and which tends to be less effective.
Fig1. Schematic diagram of NanoCMP™.
At the same time, this ability to activate killer T cells and helper T cells strongly and simultaneously is well suited for protein-based cancer vaccines. Although peptide vaccines are a trend in vaccine development today, for NanoCMP™, we still recommend the use of full-length proteins or protein fragments of a certain length as antigens. First, because full-length or certain-length proteins contain multiple epitopes, they are guaranteed to be recognized by both killer cells and helper T cells and thus activate them. Second, for that human HLA differs between individuals and may, therefore, result in different immune responses, so epitopes contained in full-length or certain-length proteins can be adapted to various types of HLA, and thus such vaccines are likely to be versatile vaccines.
Creative Biolabs has developed a variety of vaccine delivery platforms to meet the delivery of vaccines to enhance the effectiveness of vaccines. Our NanoCMP™ platform has been extensively validated to demonstrate that it not only delivers protein vaccines efficiently but also has the ability to simultaneously stimulate killer T cells and helper cells.
All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.
